SHC Sotera Health

Sterigenics Announces Expansion of Rantigny Facility to Increase European Sterilization Capacity

Sterigenics Announces Expansion of Rantigny Facility to Increase European Sterilization Capacity

OAK BROOK, IL, March 10, 2021 (GLOBE NEWSWIRE) -- Sterigenics S.A.S., a subsidiary of Sotera Health and a global leader in comprehensive sterilization services, announces the expansion of its ethylene oxide (EO) facility located in Rantigny, France to increase European sterilization capacity. The expansion increases the Rantigny facility’s total sterilization throughput and diversifies its capabilities with the addition of a 32-pallet chamber. “Local and regional demand for contract sterilization services has been increasing to meet healthcare needs,” said Pontus Rundstrom, Vice President, Operations EMEAA. “The additional capacity at Rantigny shows our commitment to our sterilization customers by helping to get their products into the market in a fast, flexible and reliable way.”

Sterigenics remains committed to addressing the growing need for sterilization in many parts of the world. The Sterigenics’ Rantigny facility provides routine EO, EOStat® rapid processing, cycle development and process validation and offers laboratory testing services through its co-located Nelson Labs facility. The Rantigny expansion follows Sterigenics’ recent acquisition of Iotron Industries, a leading electron beam provider in North America. The acquisition further expands the company’s capacity across multiple technologies throughout its global network.

About Sotera Health: Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

About Sterigenics:  is a leading global provider of outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. With our industry recognized scientific and technological expertise we help to ensure the safety of millions of patients and healthcare practitioners around the world every year. Across our 48 facilities worldwide, we offer our customers a complete range of outsourced terminal sterilization services, primarily using the three major sterilization technologies: gamma irradiation, ethylene oxide processing and electron beam irradiation and expert advisory services. We are committed to addressing the growing need for sterilization in many parts of the world and partnering with our customers to eliminate threats to human health. Safeguarding Global Health® - with every product we sterilize.

About Nelson Labs: is a global leader in outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. Nelson Labs serves over 3,800 customers across 14 facilities in the United States, Mexico, Asia and Europe. We have a comprehensive array of over 800 laboratory tests supporting our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance. We are regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. Safeguarding Global Health® - with every test we complete.

Media Contact

SOTERA HEALTH and STERIGENICS:

Kristin Gibbs

Chief Marketing Officer

 



EN
10/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sotera Health

 PRESS RELEASE

Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Pro...

Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook 2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% an...

 PRESS RELEASE

Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Rel...

Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date CLEVELAND, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2025 before the market opens on Tuesday, February 24, 2026. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s ...

 PRESS RELEASE

Sotera Health Appoints Richard Kyle to the Board of Directors

Sotera Health Appoints Richard Kyle to the Board of Directors CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle serve...

 PRESS RELEASE

Sotera Health to Showcase Continued Revenue Growth and Strategic Value...

Sotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference CLEVELAND, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, is presenting today at the 44th Annual J.P. Morgan Healthcare Conference. During the presentation, Management will be providing an update on Sotera Health’s business. “Sotera Health continued its solid g...

 PRESS RELEASE

Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Con...

Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference CLEVELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. Company representatives will also participate in investor meetings during th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch